Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers

Pediatric Infectious Disease Journal

Volumn 18, Issue 9, 1999, Pages 757-763

  Shinefield, Henry R ^a   Black, Steven ^a   Ray, Paula ^a   Chang, Ih ^b   Lewis, Ned ^a   Fireman, Bruce ^a   Hackell, Jill ^b   Paradiso, Peter R ^b   Siber, George ^b   Kohberger, Robert ^b   Madore, Dace V ^b   Malinowski, Frank J ^c   Kimura, Alan ^d   Le, Chinh ^a   Landaw, Irene ^a   Aguilar, Janet ^a   Hansen, John ^b  

^a KAISER PERMANENTE   (United States)

^b Wyeth Lederle Vaccines and Pediat   (United States)

^c Axis Genetics   (United States)

^d BioChem Pharma Inc   (United States)

Author keywords

Concurrent administration; Conjugate heptavalent pneumococcal vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; MENINGOCOCCUS VACCINE; ORAL POLIOMYELITIS VACCINE; PERTUSSIS TOXIN; PNEUMOCOCCUS VACCINE; TETANUS TOXOID;

ANTIBODY TITER; ARTICLE; BACTERIAL INFECTION; CHILD; CONTROLLED STUDY; DIPHTHERIA; DRUG SAFETY; ERYTHEMA; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HUMAN; IMMUNOGENICITY; INFANT; INJECTION SITE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; TETANUS; TREATMENT OUTCOME; VACCINATION; VIRUS INFECTION;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; INFANT; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 0032878775     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199909000-00004     Document Type: Article

References (20)

1. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997;337: 970-6.
2. Klein JO. The microbiology of otitis media. In: Wiet RJ, Coulthard SW,eds. Proceedings of the Second National Conference on Otitis Media. Columbus, OH: Ross Laboratories, 1979;43-6.
3. Shann F. Etiology of severe pneumonia in children in developing countries. Pediatr Infect Dis 1986;5:247-52.
4. Quataert SA, Kirch CS, Wiedl LJ, et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum lot 89-S. Clin Diagn Lab Immunol 1995;2:590-7.
5. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998; 101:604-11.
6. Shurin PA, Rehmus JM, Johnson CE, et al. Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high risk children. J Pediatr 1993;123:801-10.
7. Rubin LG, Mardy GV, Pais L, Carlone G. Human anticapsular antibody concentration required for protection against experimental pneumococcal bacteremia [Abstract G47]. Proceedings of the 35th Interscience Conference of Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17 to 20, 1995. Washington, DC: American Society for Microbiology, 1995.
8. Saladino RA, Stack AM, Malley R, Thompson CM, Siber CR, Fleiser GO. Bacterial polysaccharide immune globulin (BPIG) protects infant rats with S. pneumoniae (SP) pneumonia from bacteremia, meningitis and death. Pediatr Res 1996;36:184A.
9. Giebink GC, Koskela M, Vella PP, et al. Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: immunogenicity and efficacy in experimental pneumococcal otitis media. J Infect Dis 1993;167:347-55.
10. Teele DW, Klein JO, Bratton Let al. Use of pneumococcal vaccine for prevention of recurrent acute otitis media in infants in Boston. Rev Infect Dis 1981;3:S113-8.
11. Robbins JB, Parke JC Jr, Schneerson R, Whisnant JK. Quantitative measurement of "natural" and immunization-induced H. influenzae type b capsular polysaccharide antibodies. Pediatr Res 1973;7:103-10.
12. Kayhty H, Peltola H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983;147:1100.
13. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1984;149:1034-5.
14. Volk VK, Gottshall RY, Anderson HD, et al. Antigenic responses to booster dose of diphtheria and tetanus toxoids: seven to thirteen years after primary inoculation of noninstitutionalized children. Public Health Rep 1962;77:185-94.
15. McComb JA. The prophylactic dose of homologous tetanus antitoxin. N Engl J Med 1964;270:175-8.
16. Eskola J, Olander RM, Hovi T, et al. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 1996;348:1688-92.
17. IIV) in healthy children. J Infect Dis 1996;173:731-4.
18. II and TETRAMUNE® followed six weeks later by VARIVAX®. Pediatr Infect Dis J 1998;17:980-5.
19. Dagan R, Eskola J, Leclerc C, Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun 1998; 66:2093-8.
20. Black SB, Shinefield HR, Ray P, et al. Safety of combined oligosaccharide conjugate Haemophilus influenzae type b (HbOC) and whole cell diphtheria-tetanus toxoids-pertussis vaccine in infancy. Pediatr Infect Dis J 1993;12:981.